138 related articles for article (PubMed ID: 9935012)
21. Accounting for ACUITY.
Bittl JA
N Engl J Med; 2006 Nov; 355(21):2249-50. PubMed ID: 17124024
[No Abstract] [Full Text] [Related]
22. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
Campbell KR; Mahaffey KW; Lewis BE; Weitz JI; Berkowitz SD; Ohman EM; Califf RM
J Invasive Cardiol; 2000 Dec; 12 Suppl F():14F-9. PubMed ID: 11156729
[No Abstract] [Full Text] [Related]
23. HORIZONS-AMI.
Webster MW
Lancet; 2010 Jan; 375(9712):375. PubMed ID: 20113821
[No Abstract] [Full Text] [Related]
24. Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures as an alternative to heparin in interventional procedures.
Chew DP
Hamostaseologie; 2002 Aug; 22(3):60-6. PubMed ID: 12215763
[TBL] [Abstract][Full Text] [Related]
25. Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
Yusuf S
Am J Cardiol; 1999 Sep; 84(5A):20M-25M. PubMed ID: 10505539
[TBL] [Abstract][Full Text] [Related]
26. Caspofungin acetate, bivalirudin.
Am J Health Syst Pharm; 2001 Oct; 58(19):1807-9. PubMed ID: 11596694
[No Abstract] [Full Text] [Related]
27. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
28. Hirudin and hirudin analogues as new anticoagulant agents.
Pineo GF; Hull RD
Curr Opin Hematol; 1995 Sep; 2(5):380-5. PubMed ID: 9372023
[TBL] [Abstract][Full Text] [Related]
29. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R
JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942
[TBL] [Abstract][Full Text] [Related]
30. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.
Mahaffey KW; Lewis BE; Wildermann NM; Berkowitz SD; Oliverio RM; Turco MA; Shalev Y; Ver Lee P; Traverse JH; Rodriguez AR; Ohman EM; Harrington RA; Califf RM;
J Invasive Cardiol; 2003 Nov; 15(11):611-6. PubMed ID: 14608128
[TBL] [Abstract][Full Text] [Related]
31. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial.
Neuhaus KL; Molhoek GP; Zeymer U; Tebbe U; Wegscheider K; Schröder R; Camez A; Laarman GJ; Grollier GM; Lok DJ; Kuckuck H; Lazarus P
J Am Coll Cardiol; 1999 Oct; 34(4):966-73. PubMed ID: 10520777
[TBL] [Abstract][Full Text] [Related]
32. Platelet reactivity and percutaneous coronary intervention: another clue in the quest for the Holy Grail of tailored antithrombotic therapy?
Di Sciascio G; Mangiacapra F
J Am Coll Cardiol; 2012 Jul; 60(5):378-80. PubMed ID: 22682552
[No Abstract] [Full Text] [Related]
33. Anticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin?
Silvain J; Montalescot G
Arch Cardiovasc Dis; 2012 May; 105(5):259-61. PubMed ID: 22709466
[No Abstract] [Full Text] [Related]
34. Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials.
Yu J; Mehran R; Clayton T; Gibson CM; Brodie BR; Witzenbichler B; Lincoff AM; Deliargyris EN; Gersh BJ; Pocock SJ; Stone GW; Dangas GD
Catheter Cardiovasc Interv; 2016 Feb; 87(3):391-400. PubMed ID: 26624854
[TBL] [Abstract][Full Text] [Related]
35. Current anticoagulation options in percutaneous intervention: designing patient-specific strategies.
French MH; Faxon DP
Rev Cardiovasc Med; 2002; 3(4):176-82. PubMed ID: 12556751
[TBL] [Abstract][Full Text] [Related]
36. Direct thrombin inhibitors (part 2 of 2).
Arora UK; Dhir M
J Invasive Cardiol; 2005 Feb; 17(2):85-91. PubMed ID: 15687531
[No Abstract] [Full Text] [Related]
37. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.
Direct Thrombin Inhibitor Trialists' Collaborative Group
Lancet; 2002 Jan; 359(9303):294-302. PubMed ID: 11830196
[TBL] [Abstract][Full Text] [Related]
38. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators.
Lancet; 1999 Feb; 353(9151):429-38. PubMed ID: 9989712
[TBL] [Abstract][Full Text] [Related]
39. Anticoagulant therapy in unstable angina.
Choy JB; Armstrong PW
Cardiol Clin; 1999 May; 17(2):327-43, ix. PubMed ID: 10384830
[TBL] [Abstract][Full Text] [Related]
40. Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial.
Sanborn TA; Tomey MI; Mehran R; Généreux P; Witzenbichler B; Brener SJ; Kirtane AJ; McAndrew TC; Kornowski R; Dudek D; Nikolsky E; Stone GW
Catheter Cardiovasc Interv; 2015 Feb; 85(3):371-9. PubMed ID: 25179260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
